C-Rad AB (publ)
The answer first
Does C-Rad beat the market?
No, C-Rad has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 45% of Nordic stocks
- Quality81
- Value53
- Trend15
No. 69 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash C-Rad keeps must grow about 43% a year for 10 years.
Max for seven days
Follow C-Rad with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about C-Rad
Your first answer is free, no account needed.
Do you own C-Rad, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with C-Rad and a few more. Free, no card.
Super Stock+44.6%In short
- C-Rad has fallen 30.9% over the past year, including dividends.
- Overall, C-Rad ranks better than 45% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 56.9%. The price is 64.1% below its peak now.
What do analysts think of C-Rad?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 45% of Nordic stocks.
No. 69 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 49 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.05
- Asset turnoverSales divided by everything the company owns0.82
- Return on equityProfit divided by equity+12.7%
- Cash conversionOperating cash flow divided by profit0.27
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 47 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.1
- P/SPrice divided by sales1.9
- P/EPrice divided by earnings16.7
- P/CFPrice divided by operating cash flow61.7
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 143 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−31.5%
- 6 months−31.7%
- 9 months−13.1%
- 12 months−30.9%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own C-Rad
5 funds we follow own C-Rad. The share is how much of the fund the stock makes up.
- Sweden5
From the funds' latest known holdings.
About C-Rad
C-Rad AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 98 employees.
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gat…


See the full analysis of C-Rad.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card